JSM2024
Back to all people

Thomas Brechenmacher

Cytel
1 appearance in the program

Sessions & presentations

Statistical Methods for Clinical Trial Endpoints
Presentation: Seamless phase 2/3 design with Bayesian dose selection rule based on primary and surrogate endpoints
Contributed Papers · Mon, Aug 5 , 2:00 PM
First Author